Literature DB >> 16915295

mTOR and cancer: insights into a complex relationship.

David M Sabatini1.   

Abstract

mTOR (mammalian target of rapamycin) has come a long way since its humble beginnings as a kinase of unknown function. As part of the mTORC1 and mTORC2 complexes mTOR has key roles in several pathways that are involved in human cancer, stimulating interest in mTOR inhibitors and placing it on the radar of the pharmaceutical industry. Here, I discuss the rationale for the use of drugs that target mTOR, the unexpectedly complex mechanism of action of existing mTOR inhibitors and the potential benefits of developing drugs that function through different mechanisms. The purpose is not to cover all aspects of mTOR history and signalling, but rather to foster discussion by presenting some occasionally provocative ideas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16915295     DOI: 10.1038/nrc1974

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  589 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution.

Authors:  Huili Lu; Hongyu Liu; Jiaxian Wang; Jiaqing Shen; Shunyan Weng; Lei Han; Tao Sun; Lan Qian; Mingyuan Wu; Shunying Zhu; Yan Yu; Wei Han; Jianwei Zhu; Anja Moldenhauer
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-15       Impact factor: 4.553

3.  Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.

Authors:  Chia-Hung Yen; Yao-Cheng Lu; Chung-Hsien Li; Cheng-Ming Lee; Chia-Yen Chen; Ming-Yuan Cheng; Shiu-Feng Huang; Kuen-Feng Chen; Ann-Lii Cheng; Li-Ying Liao; Yan-Hwa Wu Lee; Yi-Ming Arthur Chen
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

4.  Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation.

Authors:  E Norsted Gregory; S Codeluppi; J A Gregory; J Steinauer; C I Svensson
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

5.  The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord.

Authors:  Simone Codeluppi; Camilla I Svensson; Michael P Hefferan; Fatima Valencia; Morgan D Silldorff; Masakatsu Oshiro; Martin Marsala; Elena B Pasquale
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

Review 6.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

7.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

8.  p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.

Authors:  Stuti Agarwal; Catherine M Bell; Shirley M Taylor; Richard G Moran
Journal:  Mol Cancer Res       Date:  2015-09-18       Impact factor: 5.852

Review 9.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

10.  mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.

Authors:  Debasmita Roy; Sang-Hoon Sin; Amy Lucas; Raman Venkataramanan; Ling Wang; Anthony Eason; Veenadhari Chavakula; Isaac B Hilton; Kristen M Tamburro; Blossom Damania; Dirk P Dittmer
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.